Literature DB >> 1695605

Histopathology of alpha 1-antitrypsin liver disease in a transgenic mouse model.

S A Geller1, W S Nichols, M J Dycaico, K A Felts, J A Sorge.   

Abstract

Transgenic mice were constructed using human alpha 1-antitrypsin M and Z genomic clones. Livers of the M lineage mice showed slight cellular pleomorphism and immunohistochemically demonstrable finely granular alpha 1-antitrypsin material in hepatocytes. Z lineage mice with five gene copies per haploid mouse genome (Z#1) demonstrated fine granular alpha 1-antitrypsin material and a few large globules. In contrast, Z lineage mice with 12 gene copies per haploid mouse genome (Z#2) demonstrated hepatocytes filled with homogeneous, eosinophilic globules that were strongly reactive with diastase and periodic acid-Schiff and antibody to alpha 1-antitrypsin. Scattered microscopic polymorphonuclear leukocyte accumulations were seen that contained extracellular alpha 1-antitrypsin material, but there was neither histological nor serological evidence of mouse infectious hepatitis. In young animals, small clusters of hepatocytes lacking alpha 1-antitrypsin material were seen. These cells were the dominant population in older animals and formed nodular arrangements. Fibrosis was not demonstrable in neonatal and young animals or in any of the controls, but perisinusoidal fibrosis was seen in older Z#2 mice. Groups of hepatocytes without alpha 1-antitrypsin material showed dysplastic changes. We conclude that the transgenic mouse is a reliable and useful model in which to study the effects of alpha 1-antitrypsin in the liver because it demonstrates changes similar to those in the human disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695605     DOI: 10.1002/hep.1840120108

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

Review 1.  Animal models of human amyloidoses: are transgenic mice worth the time and trouble?

Authors:  Joel N Buxbaum
Journal:  FEBS Lett       Date:  2009-07-20       Impact factor: 4.124

Review 2.  Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors.

Authors:  R Khokha; D C Martin; J E Fata
Journal:  Cancer Metastasis Rev       Date:  1995-06       Impact factor: 9.264

3.  A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver.

Authors:  Kirk J Wangensteen; Andrew Wilber; Vincent W Keng; Zhiying He; Ilze Matise; Laura Wangensteen; Corey M Carson; Yixin Chen; Clifford J Steer; R Scott McIvor; David A Largaespada; Xin Wang; Stephen C Ekker
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

4.  Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease.

Authors:  Christine I Wooddell; Keith Blomenkamp; Ryan M Peterson; Vladimir M Subbotin; Christian Schwabe; James Hamilton; Qili Chu; Dawn R Christianson; Julia O Hegge; John Kolbe; Holly L Hamilton; Maria F Branca-Afrazi; Bruce D Given; David L Lewis; Edward Gane; Steven B Kanner; Jeffrey H Teckman
Journal:  JCI Insight       Date:  2020-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.